Zoetis (ZTS) Cash from Investing Activities (2012 - 2026)
Zoetis (ZTS) reported Cash from Investing Activities of -$87.0 million for Q1 2026, up 57.14% year-over-year from -$55.4 million in Q1 2025, and up 47.59% quarter-over-quarter from -$166.0 million in Q4 2025.
Zoetis (ZTS) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Cash from Investing Activities data on file, last reported at -$87.0 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$87.0 million, up 57.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$632.0 million (down 63.31% YoY), and the FY2025 annual result was -$748.0 million, down 137.46% from the prior year.
- Cash from Investing Activities rose to -$87.0 million in Q1 2026 per ZTS's latest filing, from -$166.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $126.0 million in Q4 2024 and troughed at -$438.0 million in Q4 2022.
- A 5-year average of -$165.3 million and a median of -$166.0 million in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 160.0% in 2024, then sank 231.75% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$438.0 million in 2022, then surged by 52.05% to -$210.0 million in 2023, then soared by 160.0% to $126.0 million in 2024, then slumped by 231.75% to -$166.0 million in 2025, then jumped by 47.59% to -$87.0 million in 2026.
- Business Quant data shows ZTS's Cash from Investing Activities at -$87.0 million in Q1 2026, -$166.0 million in Q4 2025, and -$160.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 25.99 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -15.45 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn | -2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.00 Mn |
| Mar 31, 2026 | -87.00 Mn |
| Dec 31, 2025 | -166.00 Mn |
| Dec 31, 2025 | -166.00 Mn |
| Sep 30, 2025 | -160.00 Mn |
| Sep 30, 2025 | -160.00 Mn |
| Jun 30, 2025 | -219.00 Mn |
| Jun 30, 2025 | -219.00 Mn |
| Mar 31, 2025 | -203.00 Mn |
| Mar 31, 2025 | -203.00 Mn |
| Dec 31, 2024 | 126.00 Mn |
| Dec 31, 2024 | 126.00 Mn |
| Sep 30, 2024 | -178.00 Mn |
| Sep 30, 2024 | -178.00 Mn |
| Jun 30, 2024 | -132.00 Mn |
| Jun 30, 2024 | -132.00 Mn |
| Mar 31, 2024 | -131.00 Mn |
| Mar 31, 2024 | -131.00 Mn |
| Dec 31, 2023 | -210.00 Mn |
| Dec 31, 2023 | -210.00 Mn |